New insider Emerson Andrew claimed ownership of 2,396 shares (SEC Form 3)
$IDXX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/01/2025 |
3. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 2,396.436 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Restricted Stock Unit | (1) | (1) | Common Stock | 61 | (1) | D | |
| Restricted Stock Unit | (2) | (2) | Common Stock | 187 | (2) | D | |
| Restricted Stock Unit | (3) | (3) | Common Stock | 125 | (3) | D | |
| Restricted Stock Unit | (4) | (4) | Common Stock | 775 | (4) | D | |
| Restricted Stock Unit | (5) | (5) | Common Stock | 258 | (5) | D | |
| Incentive Stock Option (right-to-buy) | (6) | 02/13/2027 | Common Stock | 1,849 | $141.6 | D | |
| Incentive Stock Option (right-to-buy) | (7) | 02/13/2028 | Common Stock | 1,190 | $178.26 | D | |
| Non-Qualified Stock Option (right-to-buy) | (8) | 02/13/2029 | Common Stock | 586 | $206.94 | D | |
| Incentive Stock Option (right-to-buy) | (9) | 02/13/2029 | Common Stock | 515 | $206.94 | D | |
| Non-Qualified Stock Option (right-to-buy) | (10) | 02/13/2030 | Common Stock | 662 | $288.78 | D | |
| Incentive Stock Option (right-to-buy) | (11) | 02/13/2030 | Common Stock | 229 | $288.78 | D | |
| Non-Qualified Stock Option (right-to-buy) | (12) | 02/13/2031 | Common Stock | 230 | $544.08 | D | |
| Incentive Stock Option (right-to-buy) | (13) | 02/13/2031 | Common Stock | 183 | $544.08 | D | |
| Non-Qualified Stock Option (right-to-buy) | (14) | 02/13/2032 | Common Stock | 546 | $505.53 | D | |
| Incentive Stock Option (right-to-buy) | (15) | 02/13/2032 | Common Stock | 182 | $505.53 | D | |
| Non-Qualified Stock Option (right-to-buy) | (16) | 02/13/2033 | Common Stock | 703 | $497.43 | D | |
| Incentive Stock Option (right-to-buy) | (17) | 02/13/2033 | Common Stock | 217 | $497.43 | D | |
| Non-Qualified Stock Option (right-to-buy) | (18) | 02/13/2034 | Common Stock | 598 | $560.56 | D | |
| Incentive Stock Option (right-to-buy) | (19) | 02/13/2034 | Common Stock | 178 | $560.56 | D | |
| Non-Qualified Stock Option (right-to-buy) | (20) | 02/12/2035 | Common Stock | 4,383 | $459.76 | D | |
| Incentive Stock Option (right-to-buy) | (21) | 02/12/2035 | Common Stock | 217 | $459.76 | D | |
| Explanation of Responses: |
| 1. Remainder of a grant of 247 restricted stock units ('RSU'). Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2023. |
| 2. Remainder of a grant of 377 RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2024. |
| 3. Remainder of a grant of 167 RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. |
| 4. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2026. |
| 5. RSU grant that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. |
| 6. Grant of option to buy 1,849 shares of Issuer common stock that vested on February 14, 2022. |
| 7. Grant of option to buy 1,190 shares of Issuer common stock that vested on February 14, 2023. |
| 8. Grant of option to buy 586 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2020. |
| 9. Grant of option to buy 515 shares of Issuer common stock that vested on February 14, 2024. |
| 10. Grant of option to buy 662 shares of Issuer common stock that vested in four annual installments beginning on February 14, 2021. |
| 11. Grant of option to buy 229 shares of Issuer common stock that vested on February 14, 2025. |
| 12. Grant of option to buy 230 shares of Issuer common stock that vested in four annual installments beginning on February 14, 2022. |
| 13. Grant of option to buy 183 shares of Issuer common stock that vested on February 14, 2025. |
| 14. Grant of option to buy 546 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2023. |
| 15. Grant of option to buy 182 shares of Issuer common stock that vests on February 14, 2026. |
| 16. Grant of option to buy 703 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2024. |
| 17. Grant of option to buy 217 shares of Issuer common stock that vests on February 14, 2027. |
| 18. Grant of option to buy 598 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2025. |
| 19. Grant of option to buy 178 shares of Issuer common stock that vests on February 14, 2028. |
| 20. Grant of option to buy 4,383 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2026. |
| 21. Grant of option to buy 217 shares of Issuer common stock that vests on February 14, 2029. |
| Remarks: |
| /s/ Andrew Emerson | 03/10/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||